UBS AM’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $14M | Buy |
134,101
+59,209
| +79% | +$6.18M | ﹤0.01% | 1191 |
|
|
2025
Q1 | $8.73M | Buy |
74,892
+17,250
| +30% | +$2.01M | ﹤0.01% | 1288 |
|
|
2024
Q4 | $4.88M | Buy |
57,642
+9,928
| +21% | +$840K | ﹤0.01% | 1626 |
|
|
2024
Q3 | $4.29M | Sell |
47,714
-8,479
| -15% | -$762K | ﹤0.01% | 1654 |
|
|
2024
Q2 | $4.52M | Buy |
56,193
+27,352
| +95% | +$2.2M | ﹤0.01% | 1545 |
|
|
2024
Q1 | $2.3M | Sell |
28,841
-1,168
| -4% | -$93.2K | ﹤0.01% | 1623 |
|
|
2023
Q4 | $2.39M | Sell |
30,009
-4,391
| -13% | -$349K | ﹤0.01% | 1598 |
|
|
2023
Q3 | $2.4M | Buy |
34,400
+9,565
| +39% | +$668K | ﹤0.01% | 1530 |
|
|
2023
Q2 | $1.53M | Hold |
24,835
| – | – | ﹤0.01% | 1797 |
|
|
2023
Q1 | $1.53M | Sell |
24,835
-2,119
| -8% | -$131K | ﹤0.01% | 1797 |
|
|
2022
Q4 | $2.08M | Buy |
26,954
+1,951
| +8% | +$150K | ﹤0.01% | 1507 |
|
|
2022
Q3 | $1.12M | Buy |
25,003
+2,936
| +13% | +$131K | ﹤0.01% | 1903 |
|
|
2022
Q2 | $845K | Sell |
22,067
-892
| -4% | -$34.2K | ﹤0.01% | 2059 |
|
|
2022
Q1 | $950K | Hold |
22,959
| – | – | ﹤0.01% | 2177 |
|
|
2021
Q4 | $867K | Hold |
22,959
| – | – | ﹤0.01% | 2286 |
|
|
2021
Q3 | $757K | Sell |
22,959
-4,666
| -17% | -$154K | ﹤0.01% | 2302 |
|
|
2021
Q2 | $1.86M | Buy |
27,625
+2,778
| +11% | +$187K | ﹤0.01% | 1884 |
|
|
2021
Q1 | $1.41M | Sell |
24,847
-2,196
| -8% | -$124K | ﹤0.01% | 1917 |
|
|
2020
Q4 | $2.2M | Sell |
27,043
-630
| -2% | -$51.3K | ﹤0.01% | 1642 |
|
|
2020
Q3 | $1.97M | Buy |
27,673
+545
| +2% | +$38.8K | ﹤0.01% | 1547 |
|
|
2020
Q2 | $2.23M | Buy |
27,128
+8,635
| +47% | +$710K | ﹤0.01% | 1475 |
|
|
2020
Q1 | $1.09M | Sell |
18,493
-4,815
| -21% | -$283K | ﹤0.01% | 1666 |
|
|
2019
Q4 | $2.41M | Buy |
23,308
+10,064
| +76% | +$1.04M | ﹤0.01% | 1514 |
|
|
2019
Q3 | $268K | Sell |
13,244
-9,983
| -43% | -$202K | ﹤0.01% | 2488 |
|
|
2019
Q2 | $598K | Buy |
+23,227
| New | +$598K | ﹤0.01% | 2132 |
|